Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.71 |
| ▸ | TAS2R14 | Q9NYV8 | 7/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | CNR2 | P34972 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL984791 | 0.87 | TAS2R14 (0.71) | TAS2R14MEN1KMT2ACNR2MAPT | |
| SCHEMBL20379711 | 0.86 | BACE1 (0.60) | BACE1TAS2R14MEN1KMT2ACNR2 | |
| SCHEMBL4924397 | 0.84 | TAS2R14 (0.64) | TAS2R14MEN1KMT2ACNR2MAPT | |
| SCHEMBL4236580 | 0.83 | ALDH1A1 (0.68) | BACE1MEN1KMT2AMAPTNR3C1 | |
| SCHEMBL4413527 | 0.82 | HTR2A (0.75) | TAS2R14MEN1KMT2ACNR2MAPT | |
| SCHEMBL8911635 | 0.82 | TAS2R14 (0.78) | TAS2R14MEN1KMT2ACNR2MAPT | |
| SCHEMBL6804193 | 0.82 | CNR2 (0.85) | BACE1TAS2R14MEN1KMT2ACNR2 | |
| SCHEMBL14045854 | 0.81 | TAS2R14 (0.62) | BACE1TAS2R14MEN1KMT2ACNR2 | |
| SCHEMBL13649395 | 0.81 | TAS2R14 (0.62) | BACE1TAS2R14MEN1KMT2ACNR2 | |
| SCHEMBL4917430 | 0.81 | CNR2 (0.68) | TAS2R14MEN1KMT2ACNR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001083434-B1 | P-(SULFONYL)-ARYL AND HETEROARYLS AMINES | — | 2002-04-25 | — | — | WO | claimed |
| CN-104845355-A | Article comprising thermoplastic polyurethane and polyamide 6/66 copolymer | BASF SE | 2015-08-19 | — | — | CN | disclosed |
| US-8470829-B2 | Imidazolidine derivative and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-06-25 | — | — | US | disclosed |
| CN-102341458-A | Article comprising thermoplastic polyurethane and polyamide 6/66 copolymer | BASF SE | 2012-02-01 | — | — | CN | disclosed |
| US-20110306615-A1 | NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-12-15 | — | — | US | disclosed |
| US-7491735-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1708703-A4 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2008-04-09 | — | — | EP | disclosed |
| EP-1708703-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-10-11 | — | — | EP | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005059107-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306615-A1 | NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | CBR1, NR0B1, CNKSR1 | BACE1 4047/4885TAS2R14 1250/4885MEN1 1708/4885 |
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | BACE1 3346/4885TAS2R14 1991/4885MEN1 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.